Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Arizona
With
United Therapeutics
Age
18–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with clinically suspected World Health Organization (WHO) group I PAH
Patients with New York Heart Association/WHO functional class II-IV
Patients with mean pulmonary artery pressure \>25 mmHg, pulmonary capillary wedge pressure \</=15 mmHg, and pulmonary vascular resistance \>3 wood units
Age \>18 and \<80
No evidence of active ischemic heart disease
You may not be if
Left ventricular ejection fraction \<50%
Patients with significant restrictive lung disease (FVC \<60% predicted) and/or significant obstructive lung disease (FEV1 \<55% predicted) within 1 year of enrollment if pulmonary function testing is available
Patients with significant, investigator-determined parenchymal lung disease on chest x-ray or CT of the chest
History of pulmonary embolism within the last three months or chronic pulmonary embolism